Gastric Cancer RAD001 Study

Phase 1

Completed

• Conditions: Gastric Cancer
• Interventions: Drug: RAD001

• Registration Number: NCT01514110
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

The purpose of this study is to determine dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of RAD001, as well as to assess tumor response and overall survival.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-23
• Study First Submitted: 2011-11-22
• Study First Submitted QC: 2012-01-17
• Study First Posted: 2012-01-20
• Status Verified: 2019-03
• Primary Completion: 2019-03-06
• Study Completion: 2019-03-06
• Last Update Submitted: 2019-03-31
• Last Update Posted: 2019-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Histologically or cytologically proven adenocarcinoma of the stomach. Patients who have adenocarcinoma of the gastroesophageal junction will be eligible if the majority of the tumor bulk is below the junction.
• Metastatic or Loco-regionally advanced disease
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT /MRI scan. See section 11.2 for the evaluation of measurable disease.
• Age >= 18 years.
• Life expectancy of greater than 12 weeks.
• ECOG performance status <= 2 (Karnofsky >= 60%).

Read More

Exclusion Criteria

• Patients who have received more than one line of palliative chemotherapy are allowed, provided that (i) the prior chemotherapy does not contain taxane, cisplatin or carboplatin; (ii) 4 weeks have elapsed prior to the start of the current study treatment, and that (iii) they have recovered from adverse events due to previous treatment [except alopecia].
• Patients who have had radiotherapy or major surgery within 4 weeks prior to entering the study or those who have not recovered from adverse events due to treatment administered more than 4 weeks earlier.
• Patients who are on CYP3A4 modifiers are excluded from the study
• Patients with known brain metastases.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to RAD001.

Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure related to primary cardiac disease, a condition requiring anti-arrhythmic therapy, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the trial entry.

• Patients with severe concurrent medical illness such as severe impairment of lung function should be excluded from studies of RAD001.
• Uncontrolled intercurrent such as, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
• Poorly controlled diabetes mellitus
• High LDL cholesterol or triglyceride level
• Pre-existing neuropathy of >= grade 2
• Patients with a history of second malignancies are eligible they have been disease free for at least 5 years and are deemed by the investigator to be at low risk of recurrence. Par8entswith the following cancers are eligible if diagnosed and treated within the past 5 years: cervical carcinoma in situ, melanoma in situ, and basal cell or squamous cell carcinoma of the skin
• Pregnancy or lactation.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
RAD001	RAD001	-

Primary Outcome Measures

Name	Time	Method
to determine the Maximum tolerated dose and dose limiting toxicity of RAD001 in combination with paclitaxel and carboplatin	2 years

Secondary Outcome Measures

Name	Time	Method
Toxicity of combination Paclitaxel/carboplatin/RAD001 in advanced adenocarcinoma of the stomach and gastroesophageal junction	2 Years

Trial Locations

Locations (1)

Department of Clinical Oncology, Prince of Wales Hospital; 🇭🇰 Hong Kong, Hong Kong